The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study
- Andrew D. Zelenetz*
- , Wojciech Jurczak
- , Vincent Ribrag
- , Kim Linton
- , Graham P. Collins
- , Javier L. Jiménez
- , Mark Bishton
- , Bhagirathbhai Dholaria
- , Andrea Mengarelli
- , Tycel J. Phillips
- , Nagendraprasad Sungala
- , Gerardo Musuraca
- , Oonagh Sheehy
- , Eric Van Den Neste
- , Mitsuhiko Odera
- , Lu Miao
- , Daniel P. Gold
- , Richard G. Ghalie
- , Pier L. Zinzani
*Corresponding author for this work
- Memorial Sloan Kettering Cancer Center
- Maria Sklodowska-Curie National Research Institute of Oncology
- Institut de Cancerlogie Gustave Roussy
- GenesisCare
- Hospital Universitario Ramón y Cajal de Madrid
- National Centre for Medical Genetics
- Vanderbilt University
- IRCCS-Regina Elena National Cancer Institute
- University of Michigan
- South Western Sydney Local Health District
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
- Belfast City Hospital HSS Trust
- Universite Catholique de Louvain (Catholic University of Louvain)
- Kyowa Kirin
- MEI Pharma
- Policlinico di Sant'Orsola-Malpighi
Research output: Contribution to journal › Article › peer-review